Tracking JAKs in spondyloarthritis: rationale and expectations
- PMID: 28314752
- DOI: 10.1136/annrheumdis-2016-210886
Tracking JAKs in spondyloarthritis: rationale and expectations
Keywords: Chemokines; Cytokines; DMARDs (biologic); Spondyloarthritis; Treatment.
Conflict of interest statement
Competing interests: I have participated and I am participating at advisory boards organised by pharmaceutical companies such as Pfizer and Lilly to discuss the role of JAK inhibitors in axial SpA.
Comment on
-
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.Ann Rheum Dis. 2017 Aug;76(8):1340-1347. doi: 10.1136/annrheumdis-2016-210322. Epub 2017 Jan 27. Ann Rheum Dis. 2017. PMID: 28130206 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical